Related Experiment Video
Updated: Aug 8, 2026
13:41
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Immunogenicity of recombinant human interleukin-3
1Sandoz Pharma, East Hanover, New Jersey, USA.
Clinical Immunology and Immunopathology
|April 1, 1997
Summary
Most recombinant proteins trigger an immune response, leading to antibody formation within two weeks. For recombinant human interleukin-3 (rhIL-3), these antibodies reduced its bioavailability in Rhesus monkeys.
Area of Science:
- Immunology
- Pharmacology
- Biotechnology
Background:
- Recombinant human (rh) proteins frequently induce immune responses in animal models.
- Antibody detection typically occurs 1-2 weeks post-administration.
- Understanding rh protein immunogenicity is crucial for research and clinical applications.
Purpose of the Study:
- To investigate the immunogenicity of recombinant human proteins.
- To assess the impact of neutralizing antibodies on protein bioavailability, using rhIL-3 as a model.
Main Methods:
- Administration of rh proteins to experimental animals.
- Detection of antibodies post-administration.
- Quantification of protein bioavailability in the presence of antibodies.
Main Results:
- Most rh proteins elicited detectable antibody responses within 1-2 weeks.
- Neutralizing antibodies against rhIL-3 were formed.
- The presence of neutralizing anti-rhIL-3 antibodies significantly reduced the absolute bioavailability of rhIL-3 in Rhesus monkeys.
Conclusions:
- Recombinant human proteins are immunogenic and can stimulate antibody production.
- Neutralizing antibodies can impair the pharmacokinetic profile of rh proteins.
- This highlights the importance of considering immunogenicity in the development and use of rh proteins.
